Single center, decentralized, parallel group, open, non-randomized, long-term safety follow-up, and exploratory study of long-term effects on inflammatory, immunological, and aging related biomarkers in study participants treated with MSCs.

Status

Not yet recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517011-74-01

Acronym

2024-001-SWE

Enrollment

200

Registered

2025-01-08

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Not possible to specify

Brief summary

Adverse Event and Serious Adverse Event rates, including clinically significant laboratory abnormalities.

Detailed description

Change from baseline and after MSC treatment in EQ-5D-5L dimensions, Change from baseline in laboratory parameters.

Interventions

DRUGStromaForte MSC solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Adverse Event and Serious Adverse Event rates, including clinically significant laboratory abnormalities.	—

Secondary

Measure	Time frame
Change from baseline and after MSC treatment in EQ-5D-5L dimensions, Change from baseline in laboratory parameters.	—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026